Skip to main content
SpringerLink
Log in

A Cross-Sectional Study on Drug Use in Multiple System Atrophy

  • Original Research Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Background

Drug use has rarely been studied in multiple system atrophy (MSA) while such patients receive many treatments based on weak evidence.

Objective

To analyze drug use from the database of the French MSA Reference Center, and to compare it with data from patients with Parkinson disease (PD).

Methods

Medication of 147 MSA and 180 age- and sex-matched PD patients was analyzed. Motor and autonomic symptoms were explored in MSA patients by the SCOPA-Autonomic and Unified MSA Rating Scale (UMSARS).

Results

MSA and PD patients received a mean of five different drugs. MSA patients were more frequently exposed to laxatives, antidiabetic medications, antihypotensives, muscarinic antagonists, alpha-adrenergic blockers, and antidepressants. Levodopa consumption was less in MSA-C (cerebellar) patients compared with MSA-P (parkinsonian) and PD patients. Dopamine agonists were more consumed by PD than MSA patients. MSA patients with more severe disability received more laxatives, anticoagulants, and antidepressants. MSA-P patients received more analgesics. “Probable” MSA patients received more antihypotensives and less alpha-adrenergic blockers. Patients with higher SCOPA-Autonomic scores were more frequently on antihypotensives or antidepressants. Drug associations leading to potential adverse interactions were uncommon (usually <5 %).

Conclusions

Some differences in drug use between MSA and PD patients were observed and expected, including those used for the relief of parkinsonian motor symptoms, autonomic dysfunction, and depression. Many of these drugs are frequently used in MSA in the absence of well-established, positive, benefit-risk evaluations, thus calling for better assessments. The reason why other medications, including anti-diabetic medications, were more consumed by MSA patients remains unclear and deserves further exploration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stefanova N, Bucke P, Duerr S, et al. Multiple system atrophy: an update. Lancet Neurol. 2009;8:1172–8.

    Article  CAS  PubMed  Google Scholar 

  2. Wenning GK, Geser F, Poewe W. Therapeutic strategies in multiple system atrophy. Mov Disord. 2005;20(Suppl 12):S67–76.

    Article  PubMed  Google Scholar 

  3. Lee D, Bergman U. Studies of drug utilization. In: Strom BL, editor. Pharmacoepidemiology. Chichester: Wiley; 2000. p. 463–82.

    Chapter  Google Scholar 

  4. Centre de référence de l’atrophie multysistématisée. http://www.chu-toulouse.fr/-centre-de-reference-de-l-atrophie-multisystématisée (Accessed 2013 Oct. 15).

  5. Les Maladies Rares. http://www.sante.gouv.fr/les-maladies-rares.html (Accessed 2013 Oct. 15).

  6. Wenning GK, Tison F, Seppi K, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord. 2004;19:1391–402.

    Article  PubMed  Google Scholar 

  7. Damon-Perriere N, Foubert-Samier A, De Cock VC, et al. Assessment of the SCOPA-Aut questionnaire in multiple system atrophy: relation to UMSARS scores and progression over time. Parkinsonism Relat Disord. 2012;18:612–5.

    Article  PubMed  Google Scholar 

  8. Pavy-Le TA, Amarenco G, Duerr S, et al. The movement disorders task force review of dysautonomia rating scales in Parkinson’s disease with regard to symptoms of orthostatic hypotension. Mov Disord. 2011;26:1985–92.

    Article  Google Scholar 

  9. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Perez-Lloret S, Rey MV, Fabre N, et al. Do Parkinson’s disease patients disclose their adverse events spontaneously? Eur J Clin Pharmacol. 2012;68:857–65.

    Article  PubMed  Google Scholar 

  11. Hughes AJ, Ben-Shlomo Y, Daniel SE, et al. What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology. 1992;42:1142–6.

    Article  CAS  PubMed  Google Scholar 

  12. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2012, Oslo 2011.

  13. Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25:2649–53.

    Article  PubMed  Google Scholar 

  14. Fahn S, Elton RL, Members of the UPDRS committee. Unified Parkinson’s Disease Rating Scale. In: Fahn S, Mardsen CD, Goldstein M, editors. Recent developments in Parkinson’s disease. New York: McMillan; 1987. p. 153–63.

    Google Scholar 

  15. Ludbrook J. Multiple comparison procedures updated. Clin Exp Pharmacol Physiol. 1998;25:1032–7.

    Article  CAS  PubMed  Google Scholar 

  16. Kollensperger M, Geser F, Ndayisaba JP, et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European Multiple System Atrophy Registry. Mov Disord. 2010;25:2604–12.

    Article  PubMed  Google Scholar 

  17. Gilman S, Low P, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy: American Autonomic Society and American Academy of Neurology. Clin Auton Res. 1998;8:359–62.

    Article  CAS  PubMed  Google Scholar 

  18. Perez-Lloret S, Rascol O. Dopamine receptor agonists for the treatment of early or advanced Parkinson’s disease. CNS Drugs. 2010;24:941–68.

    Article  CAS  PubMed  Google Scholar 

  19. Trujillo-Martin MM, Serrano-Aguilar P, Monton-Alvarez F, et al. Effectiveness and safety of treatments for degenerative ataxias: a systematic review. Mov Disord. 2009;24:1111–24.

    Article  PubMed  Google Scholar 

  20. Colosimo C, Morgante L, Antonini A, et al. Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. J Neurol. 2010;257:5–14.

    Article  PubMed  Google Scholar 

  21. Papatsoris AG, Papapetropoulos S, Singer C, et al. Urinary and erectile dysfunction in multiple system atrophy (MSA). Neurourol Urodyn. 2008;27:22–7.

    Article  CAS  PubMed  Google Scholar 

  22. Sakakibara R, Hattori T, Uchiyama T, et al. Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. J Auton Nerv Syst. 2000;79:191–5.

    Article  CAS  PubMed  Google Scholar 

  23. Cameron AP, Jimbo M, Heidelbaugh JJ. Diagnosis and office-based treatment of urinary incontinence in adults: part two. Treatment. Ther Adv Urol. 2013;5:189–200.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Wenning GK, Colosimo C, Geser F, et al. Multiple system atrophy. Lancet Neurol. 2004;3:93–103.

    Article  PubMed  Google Scholar 

  25. Tison F, Yekhlef F, Chrysostome V. Depression and self-reported depressive symptoms in multiple system atrophy compared to Parkinson’s disease. Mov Disord. 2006;21:1056–7.

    Article  PubMed  Google Scholar 

  26. Bondon-Guitton E, Perez-Lloret S, Bagheri H, et al. Drug-induced parkinsonism: a review of 17 years’ experience in a regional pharmacovigilance center in France. Mov Disord. 2011;26:2226–31.

    Article  PubMed  Google Scholar 

  27. Licht CM, de Geus EJ, van Dyck R, et al. Longitudinal evidence for unfavorable effects of antidepressants on heart rate variability. Biol Psychiatry. 2010;68:861–8.

    Article  CAS  PubMed  Google Scholar 

  28. Cereda E, Barichella M, Pedrolli C, et al. Diabetes and risk of Parkinson’s disease: a systematic review and meta-analysis. Diabetes Care. 2011;34:2614–23.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Chrysostome V, Tison F, Yekhlef F, et al. Epidemiology of multiple system atrophy: a prevalence and pilot risk factor study in Aquitaine, France. Neuroepidemiology. 2004;23:201–8.

    Article  CAS  PubMed  Google Scholar 

  30. Farzamnia H, Rabiei K, Sadeghi M, et al. The predictive factors of recurrent deep vein thrombosis. ARYA Atheroscler. 2011;7:123–8.

    PubMed Central  PubMed  Google Scholar 

  31. Schrag A, Sheikh S, Quinn NP, et al. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord. 2010;25:1077–81.

    Article  PubMed  Google Scholar 

  32. Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. Expert Opin Drug Saf. 2012;11:83–94.

    Article  CAS  PubMed  Google Scholar 

  33. Schmidt C, Berg D, Prieur S, et al. Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. Mov Disord. 2009;24:2136–42.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

MVR, SPLL, APL, WM, and FT do not have any conflicts of interest to disclose in relation to this study. OR has acted as an advisor for many pharmaceutical companies developing treatments for MSA. No funding was received for the conduct of this study.

Author information

Authors and Affiliations

  1. Departments of Clinical Pharmacology and Neurosciences, Faculty of Medicine, University Hospital and University of Toulouse 3, 37 Allées Jules Guesde, 31000, Toulouse, France

    María Verónica Rey, Santiago Perez-Lloret, Anne Pavy-Le Traon & Olivier Rascol

  2. INSERM UMR825 and CIC9302, Toulouse, France

    María Verónica Rey, Santiago Perez-Lloret, Anne Pavy-Le Traon & Olivier Rascol

  3. French Reference Center for MSA, Toulouse University Hospitals, Toulouse, France

    Anne Pavy-Le Traon & Olivier Rascol

  4. French Reference Center for MSA, University Hospital Bordeaux, Bordeaux, France

    Wassilios G. Meissner & Francois Tison

  5. Institut des Maladies Neurodégénératives, UMR 5293, Université de Bordeaux, Bordeaux, France

    Wassilios G. Meissner & Francois Tison

  6. CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France

    Wassilios G. Meissner & Francois Tison

Authors
  1. María Verónica Rey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Santiago Perez-Lloret
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anne Pavy-Le Traon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wassilios G. Meissner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Francois Tison
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Olivier Rascol
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to María Verónica Rey.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rey, M.V., Perez-Lloret, S., Pavy-Le Traon, A. et al. A Cross-Sectional Study on Drug Use in Multiple System Atrophy. CNS Drugs 28, 483–490 (2014). https://doi.org/10.1007/s40263-014-0159-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-014-0159-1

Keywords

Search

Navigation